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Despite histological evidence in various solid tumor entities, available experience with
CXCR4-directed diagnostics and endoradiotherapy mainly focuses on hematologic
diseases. With the goal of expanding the application of CXCR4 theranostics to solid
tumors, we aimed to elucidate the feasibility of CXCR4-targeted imaging in a variety of
such neoplasms.
Methods: Nineteen patients with newly diagnosed, treatment-naïve solid tumors
including pancreatic adenocarcinoma or neuroendocrine tumor, cholangiocarcinoma,
hepatocellular carcinoma, renal cell carcinoma, ovarian cancer, and prostate cancer
underwent [68Ga]Pentixafor PET/CT. CXCR4-mediated uptake was assessed both
visually and semi-quantitatively by evaluation of maximum standardized uptake values
(SUVmax) of both primary tumors and metastases. With physiologic liver uptake as
reference, tumor-to-background ratios (TBR) were calculated. [68Ga]Pentixafor findings
were further compared to immunohistochemistry and [18F]FDG PET/CT.
Results: On [68Ga]Pentixafor PET/CT, 10/19 (52.6%) primary tumors were visually
detectable with a median SUVmax of 5.4 (range, 1.7–16.0) and a median TBR of 2.6
(range, 0.8–7.4), respectively. The highest level of radiotracer uptake was identified in
a patient with cholangiocarcinoma (SUVmax, 16.0; TBR, 7.4). The relatively low uptake
on [68Ga]Pentixafor was also noted in metastases, exhibiting a median SUVmax of
4.5 (range, 2.3–8.8; TBR, 1.7; range, 1.0–4.1). A good correlation between uptake
on [68Ga]Pentixafor and histological derived CXCR4 expression was noted (R = 0.62,
P < 0.05). In the 3 patients in whom [18F]FDG PET/CT was available, [68Ga]Pentixafor
exhibited lower uptake in all lesions.
Conclusions: In this cohort of newly diagnosed, treatment-naïve patients with
solid malignancies, CXCR4 expression as detected by [68Ga]Pentixafor-PET/CT and
immunohistochemistry was rather moderate. Thus, CXCR4-directed imaging may not
play a major role in the management of solid tumors in the majority of patients.
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INTRODUCTION
C-X-C motif chemokine receptor 4 (CXCR4) is overexpressed
in more than 20 tumor types and plays a crucial role in tumor
growth, tumor invasiveness, cancer cell-microenvironment
interaction, and metastasis (1, 2). Notably, the presence of
CXCR4 has been linked to unfavorable outcomes in multiple
different tumor entities, including hematologic malignancies,
breast cancer, renal cell carcinoma, gynecologic malignancies,
pancreatic adenocarcinoma, and hepatocellular carcinoma (3).
[68Ga]Pentixafor is a radiolabelled CXCR4 ligand that allows
for sensitive and high-contrast visualization of the presence of
the receptor in vivo (4, 5). Its use for non-invasive whole-
body positron emission tomography (PET) imaging has been
demonstrated in multiple (mainly hematologic) malignancies
and also inflammatory disease conditions (6–14). Additionally,
90Y- or 177Lu-labeled Pentixather (15), the therapeutic partner
of [68Ga]Pentixafor, has successfully been introduced for the
treatment of hematologic neoplasias such as multiple myeloma,
diffuse large B cell lymphoma, and acute myeloid leukemia
(16–20).
In solid malignancies, pilot studies have hinted at a role
for CXCR4-directed imaging in various selected diseases, such
as small cell lung cancer, esophageal adenocarcinoma, and
poorly differentiated neuroendocrine neoplasms (21–23). Of
note, Blümel et al. reported on the use of [68Ga]Pentixafor
in patients diagnosed with adrenocortical cancer, with 70%
of the subjects being potentially suitable for a treatment with
[177Lu]/[90Y]Pentixather (24).
On the other hand, Vag et al. could not detect relevant
[68Ga]Pentixafor uptake in a heterogenous subset of different
solid cancers, including non-small cell lung cancer, malignant
melanoma, sarcoma, cancer of unknown primary (CUP), or
breast cancer (25). Our group reported on rather discouraging
results in a small cohort of patients with malignant pleural
mesothelioma (26).
Thus, given these contradictory findings among different
solid tumor entities, we aimed to broaden the experience of
CXCR4-targeted PET imaging in solid cancers by investigating a
subset of different tumors, including cholangiocarcinoma (CCC),
hepatocellular carcinoma (HCC), pancreatic adenocarcinoma or
neuroendocrine tumor, and ovarian cancer.
MATERIALS AND METHODS
[68Ga]Pentixafor was administered on a compassionate use basis
in compliance with §37 of the Declaration of Helsinki and
The German Medicinal Products Act, AMG §13.2b. All patients
underwent imaging for clinical purposes and gave written
and informed consent to the diagnostic procedures. The local
institutional review board waived the requirement for additional
approval because of the retrospective character of this study.
Patients
Between September, 2014 and August, 2015, 19 patients
(11 males, 8 females; aged 71 ± 7 years; range, 60–
81 y) with newly diagnosed, treatment-naive solid tumors
underwent [68Ga]Pentixafor-PET/computed tomography (CT)
for assessment of CXCR4 expression. In 3/19 (15.8%) subjects,
additional [18F]FDG PET/CT was also performed for staging
purposes within 2 weeks after [68Ga]Pentixafor-PET (interval
between both scans, median 8 days; range, 1–12 d).
Following imaging, 17/19 (89.5%) subjects underwent
either tumor biopsy (8/17, 47.1%) or surgery (n = 9/17,
52.9%) after a median of 4.5 days (range, 1–55 d). Table 1
gives an overview of the clinical information for this
patient cohort.
Synthesis of [68Ga]Pentixafor
68Ga]Pentixafor was synthesized as previously described using a
fully GMP compliant automated synthesizer (GRP, Scintomics,
Fürstenfeldbruck, Germany) (27).
PET Imaging
All PET/CT scans were performed on a dedicated PET/CT
scanner (Siemens Biograph mCT 64; Siemens Healthineers,
Erlangen, Germany). Before acquisition of [18F]FDG PET,
patients fasted for at least 6 h and blood glucose levels were
<160 mg/dl. Prior to [68Ga]Pentixafor, patients did not fast.
Imaging was performed 60min after administration of 64–166
MBq (median, 145 MBq) of [68Ga]Pentixafor and 297 (n = 1)
or 301 (n = 2) MBq of [18F]FDG, respectively. Spiral CT with
(dose modulation with a quality reference of 210 mAs) or
without (80mAs) intravenous contrast (120 kV, 512× 512matrix,
5mm slice thickness) including a field of view from the base
of the skull to the proximal thighs was acquired. Consecutively,
PET emission data were acquired in three-dimensional mode
with a 200 × 200 matrix with 2–3min emission time per bed
position. After decay and scatter correction, PET data were
reconstructed iteratively with attenuation correction using the
algorithm implemented by the manufacturer (Siemens Esoft,
Siemens Healthineers, Erlangen, Germany).
Image Analysis
All PET/CT studies were visually assessed by two experienced
nuclear medicine physicians (RAW and CL). Lesions were rated
as visually detectable if they could be identified by both reviewers
on the PET images in a consensus setting.
For derivation of maximum standardized uptake values
(SUVmax) of both primary tumors (all patients) and metastatic
disease (if present, in n = 7/19, 36.8%), 3-dimensional volumes
of interest (VOI) were drawn around the respective lesions.
If patients displayed more than 5 metastases (all histologically
proven or verified by imaging follow-up), the five lesions with
the highest uptake were selected. For calculation of tumor-to-
background ratios (TBR), VOIs with a diameter of 3 cm were
placed in normal liver parenchyma and mean SUV were noted.
The radiotracer concentration in the VOI was normalized to the
injected dose per kilogram of patient’s body weight to derive the
SUVs (22).
For [18F]FDG-PET/CT, an analogous procedure was
carried out.
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TABLE 1 | Overview of included subjects.
Patient no. Tumor
entity
Grading* TNM* Visually
detectable
lesions on PET
Primary on [68Ga]Pentixafor PET Metastases on [68Ga]Pentixafor
PET
IRS
SUVmax TBR VD SUVmax TBR VD
1 CCC G2 – 1 4.65 1.68 0 – – 0/1 0
2 RCC G2 pT1b pNX Mx 1 1.88 0.88 0 – – 0/1 1
3 Pancreas
(NET)
G1 – 3 5.77 2.68 1 2.92 1.36 2/3 9
4 Pancreas
(NET)
G2 – >5 4.83 1.74 1 – – 0/5 3
5 PDAC – pT3 Nx Mx 1 7.13 2.57 0 – – 0/1 4
6 CUP – – 3 – – 0 2.33 0.96 3/3 0
7 CCC – Tx Nx M1 3 16 7.41 1 8.83 4.09 2/3 12
8 HCC – – 0 4.39 2.71 0 – – – –
9 Ovarian
(low-grade
serous)
– pT2b N1 Mx 2 9.41 4.22 1 3.84 1.72 1/2 6
10 Prostate – – 0 1.7 0.85 0 – – – –
11 PDAC – – 0 7.58 3.72 1 – – – 9
12 CCC G3 pT1 pNx Mx 2 12.09 5.02 1 6.67 2.77 1/2 2
13 HCC G3 pT2 pNx Mx 1 4.97 3.88 1 – – 0/1 0
14 PDAC – – 1 8.22 2.07 1 – – 0/1 6
15 Ovarian
(granulosa
cell tumor)
– pT1a pNx Mx 1 2.69 1.48 0 – – 0/1 0
16 PDAC G2 pT2 pN1 Mx >5 9.22 3.35 1 4.45 1.62 1/5 2
17 HCC G3 pT1 pN0 Mx 0 3.74 1.33 0 – – 0/1 0
18 Ovarian
(high-grade
serous)
G3 pT3c Nx Mx >5 2.26 1.06 0 – – 0/5 3
19 CCC – – 4 6.48 3.54 1 7.84 4.11 4/4 2
PET, positron emission tomography; IRS, immunoreactive score; SUVmax , maximum standardized uptake value; TBR, tumor to background ratio; VD, visual detectability; CCC,
cholangiocellular carcinoma; RCC, renal cell carcinoma; NET, neuroendocrine tumor; PDAC, pancreatic ductal adenocarcinoma; CUP, cancer of unknown primary; HCC, hepatocellular
carcinoma. All patients underwent [68Ga]Pentixafor PET/CT, while in 3/19 subjects, additional [18F]FDG PET/CT was performed. *prior to CXCR4-directed imaging.
Histological Tumor Characterization
Immunohistochemistry was performed on 10% formalin fixed
paraffin embedded tissue sections (3µm) and scored as
previously described (28). CXCR4-immunohistochemistry was
conducted using an anti-CXCR4 rabbit polyclonal antibody
(ab2074; Abcam, Cambridge, United Kingdom) followed by
detection with the DAKO en vision system according to
the manufacturer’s protocol. All immunostained sections were
counterstained for 3min with hematoxylin. The analysis of
the stained sections was done semi-quantitatively by light-
microscopy according to the immunoreactive score (IRS) by
Remmele and Stegner (29). The percentage of CXCR4-positive
cells was scored as follows: 0 (no positive cells), 1 (<10% positive
cells), 2 (10–50% positive cells), 3 (>50–80% positive cells), and
4 (>80% positive cells). Additionally, the intensity of staining
was graded: 0 (no color reaction), 1 (mild reaction), 2 (moderate
reaction), 3 (intense reaction). Multiplication of both scores for
a given sample yields the IRS classification: 0–1 (negative), 2–
3 (mild), 4–8 (moderate), 9–12 (strongly positive). For a more
detailed description please refer to Werner et al. (22). IRS were
correlated with imaging findings.
Statistical Analysis
Descriptive statistics were predominantly utilized. All results are
displayed asmean± SD or asmedian+ range where appropriate.
The two-tailed paired Student’s t-test was used to check for
a correlation between [68Ga]Pentixafor SUVmax and histologic
CXCR4 expression. A P-value of <0.05 was considered to be
statistically significant.
RESULTS
Clinical Findings
All patients presented with newly diagnosed, treatment-naïve
solid tumors. The following histologic entities were represented
in the cohort: pancreatic ductal adenocarcinoma (n = 4),
pancreatic neuroendocrine tumor (n = 2, initially suspected as
adenocarcinoma), CCC (n = 4), HCC (n = 3), and ovarian
cancer (n = 3, one low- and one high-grade serous carcinoma
as well as one granulosa cell tumor of the ovary, respectively).
The remaining three subjects had, renal cell carcinoma (RCC),
prostate cancer, and CUP, respectively. Evidence of metastases
was detected in 7/19 (36.8%) patients.
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Patient details are provided in Table 1.
Imaging Results of [68Ga]Pentixafor
PET/CT
On a visual basis, 10/19 (52.6%) primary tumors and 14/49
(28.6%)metastases were detectable. In semi-quantitative analysis,
the median SUVmax of the primary was 5.4 (range, 1.7–16.0) with
a median TBR of 2.6 (range, 0.8–7.4). The highest SUVmax were
identified in patients suffering from CCC (#7, SUVmax, 16.0; #12,
SUVmax, 12.1; Table 1).
Metastases exhibited a median SUVmax of 4.5 (range, 2.3–8.8)
with a TBR of 1.7 (range, 1.0–4.1).
Comparison of [68Ga]Pentixafor PET/CT
With [18F]FDG PET/CT
In 3/19 (15.8%) patients (#3, #8, and #10), an additional
[18F]FDG PET/CT scan was conducted. The primary
tumor was identified in all subjects, while it was not
visualized in 2/3 by [68Ga]Pentixafor (#8 and #10). In
semi-quantitative assessment, both SUVmax and TBR were
higher than on CXCR4-directed imaging: Median SUVmax
of the primary was 14.3 (14.3, 18.0, 9.0; [68Ga]Pentixafor,
4.4; 5.8, 4.4, 1.7, respectively) with a median TBR
of 4.8 (range, 2.9–6.7; [68Ga]Pentixafor, 2.7; 2.7, 2.7,
0.8, respectively).
[18F]FDG PET/CT detected metastases in 2/3 (#3 and #8)
patients with a median SUVmax of 13.3 (range, 11.5–16.6) and
a median TBR of 4.7 (range, 3.9–5.6) whereas [68Ga]Pentixafor
visualized only 2 metastases in patient #3 (SUVmax, 3.9 and
2.0, respectively).
Immunohistochemical Assessment
A total of 17 samples could be investigated in a pathological
assessment. 5/17 samples (29.4%) were rated as negative, 6/17
(35.4%) as “weakly” positive (IRS score 1–3), 3/17 (17.6%) as
“moderately” positive (IRS scores 4–8), and 3/17 (17.6%) as
“strongly” positive (IRS scores 9–12) (Table 1). Notably, both
membranous as well as intra-cytoplasmatic staining for CXCR4
was confirmed.
In 16/17 (94.1%), imaging results (SUVmax of the primary)
could be compared to immunohistological CXCR4 staining,
while in 1/17 (5.9%) a SUVmax could not be derived as the
primary could not be identified (#6, suffering from CUP).
A significant correlation between IRS and [68Ga]Pentixafor
SUVmax of the primary among all tumor entities was detected
(R = 0.62, P < 0.05, Figure 1). Figure 2 shows concordant
cases of immunohistochemistry and non-invasive imaging in
patients suffering from CCC (patient #7) and HCC (patient #17),
respectively. Figure 3 demonstrates CXCR4-directed imaging
in further selected tumor entities which (with the exception
of patient #9 suffering from low-grade ovarian carcinoma)
primarily demonstrated moderate to no uptake on CXCR4-
directed imaging.
FIGURE 1 | Correlation between immunoreactive score (IRS) vs.
[68Ga]Pentixafor SUVmax of the primary among all tumor entities available for
analysis R = 0.62.
DISCUSSION
An extensive body of literature has demonstrated that over-
expression of CXCR4 is linked with increased aggressiveness and
worse prognosis in solid cancers. Thus, this chemokine receptor
is an interesting target in oncology and several therapeutic
antagonists have been developed (30, 31). A recent phase I
trial in women with advanced HER-2 negative metastatic breast
cancer investigated a combination regimen of balixafortide (a
peptidic CXCR4 antagonist) and eribulin and demonstrated
favorable safety and tolerability as well as promising anti-tumor
activity (32). Additionally, a first experience with chemokine
receptor-directed radioligand therapy in heavily pre-treated
hematologic disease has been reported (17–19).
As an important pre-requisite to CXCR4 directed therapy,
[68Ga]Pentixafor PET/CT enables the non-invasive evaluation of
receptor expression of all tumor lesions. Marked inter- and intra-
individual differences in CXCR4 expression have been noted
(33). Further, the receptor presentation on the tumor cell surface
seems to be highly dynamic and influenced by a variety of factors
including previous therapy (34).
In this study, we aimed to expand the experience with non-
invasive imaging of CXCR4 in solid cancers. Previous reports
had hinted at a potential role of chemokine-directed imaging in
selected entities such as small cell lung cancer, adrenocortical
carcinoma, or glioblastoma (21, 24, 35), while another study by
Vag et al. questioned its suitability in other tumors including
sarcoma, pancreatic cancer, and breast cancer (25). In the present
analysis, additional solid cancers in which CXCR4 expression had
been linked to metastasis and inferior outcomes such as renal cell
cancer (36), ovarian cancer (37), and CCC (38) were investigated.
All patients presented with newly diagnosed, treatment-naïve
disease. To exclude potential influence of concomitant therapy
on receptor surface expression, biopsies, and/or surgery were
performed shortly after PET imaging and prior to treatment
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FIGURE 2 | Concordance of immunohistochemistry (IHC) and non-invasive CXCR4-directed positron emission tomography (PET) imaging in patients suffering from
cholangiocellular carcinoma (CCC, upper row, patient #7) and hepatocellular carcinoma (HCC, lower row, patient #17). Upper row (patient #7): Display of transaxial
PET (left), computed tomography (CT, second panel) and fused PET/CT (third panel) images of a left liver lesion. The lesion demonstrates high CXCR4 expression,
which could be confirmed in the surgical specimen after tumor resection (IHC, fourth panel). The immunoreactive score (IRS) was 12 (Table 1). Lower row (patient
#17): Display of transaxial PET (left), CT (second panel) and fused PET/CT (third panel) images of the primary. The lesions demonstrates no CXCR4 expression on PET.
The patient presented with negative IHC for CXCR4 derived from a surgical specimen (IRS, 0, Table 1). Magnification of IHC: × 400.
FIGURE 3 | Maximum intensity projections of CXCR4-directed positron emission tomography of other selected tumor entities, primarily demonstrating moderate to
no uptake on CXCR4-directed imaging (arrows). Pancreatic ductal adenocarcinoma [PDCA; (A)], pancreatic neuroendocrine tumor [PNET; (B)], ovarian cancer (C),
renal cell carcinoma [RCC; (D)], prostate cancer [PCA; (E)], and cancer of unknown primary (CUP) with multiple liver metastases (F). Only the tumor masses of the
patient with low-grade ovarian carcinoma (patient #9) display relevant CXCR4 expression.
initiation. However, only weak to moderate [68Ga]Pentixafor
uptake was recorded in the vast majority of patients and almost
80% of lesions could not be visually detected. In addition,
only two patients exhibited primary tumor SUVmax > 10.
Interestingly, both patients suffered from CCC (#7, Figure 2 and
#12). These findings were paralleled by immunohistochemistry
that also identified relevant CXCR4 expression in few tumor
specimens and correlated well with non-invasive imaging results
(R= 0.62, Figure 1).
Taken together, the current findings indicate that
[68Ga]Pentixafor is unlikely to play a major role in staging and
re-staging of most solid tumors, in particular when compared
to [18F]FDG. Given the physiologic expression of CXCR4 on
hematopoietic stem cells and thus the need for subsequent
stem cell support (17, 18), endoradiotherapy with radiolabelled
Pentixather might also be reserved to very selected cases.
Future efforts for potential applications of CXCR4-directed
imaging might focus on the characterization of intra-/inter-
lesional heterogeneity by performing dual-radiotracer studies
(in conjunction with [18F]FDG) to visualize different levels of
tumor de-differentiation and predict lesions with prognostic
relevance. For example, CXCR4-directed PET/CT might help to
visualize receptor positive cancer stem cells (and their niche)
which are considered to be especially resistant to radiation or
chemotherapy (1, 39).
Several limitations of the present study have to be considered.
It is retrospective and the number of patients is rather small.
Further research including a higher number of subjects is
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definitely warranted to confirm the preliminary findings of the
present feasibility study. Histologic validation of imaging results
was not available in all cases. Additionally, a variety of different
tumor entities were included. However, all patients presented
with newly diagnosed disease and were treatment-naïve at the
time of imaging. Moreover, in only 3 patients, an additional
[18F]FDG PET/CT has been conducted and future studies should
evaluate potential tumor heterogeneity in a higher number of
subjects. Although the value of [68Ga]Pentixafor PET/CT has
been investigated before, our small series adds first experience
with other tumor entities such as ovarian cancer and renal cell
carcinoma, along with histopathologic proof in the majority of
the cases.
CONCLUSIONS
In this cohort of various treatment-naïve solid malignancies,
CXCR4 expression as detected by [68Ga]Pentixafor-PET/CT and
immunohistochemistry was rather moderate. Thus, CXCR4-
directed imaging may not play a major role in the management
of the majority of solid cancer patients.
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